A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction (LYNK-003)

This Study is
No Longer Enrolling

Details
Age

Adult

Type of Study

Treatment

Scope

National

Locations

Greeley Campus
Harmony Campus
Medical Center of the Rockies
Poudre Valley Hospital

Study ID

Protocol Number: 19-6102

More information available at ClinicalTrials.gov: NCT04456699

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers